Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Wolkin

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Clinical Neuropharmacology|October 1, 1996
The study of neurotransmitter interactions using positron emission tomography and functional couplingR Schloesser, P Simkowitz, E J Bartlett, et al.
Biological Psychiatry|November 1, 1993
Elevated PLA2 activity in schizophrenics and other psychiatric patientsM Noponen, M Sanfilipo, K Samanich, et al.
The American Journal of Psychiatry|August 12, 1998
Structural magnetic resonance image averaging in schizophreniaA Wolkin, H Rusinek, G Vaid, et al.
The American Journal of Psychiatry|May 1, 1985
Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomographyA Wolkin, J Jaeger, J D Brodie, et al.
Archives of General Psychiatry|May 1, 1989
Dopamine receptor occupancy and plasma haloperidol levelsA Wolkin, J D Brodie, F Barouche, et al.
Schizophrenia Bulletin|February 7, 2001
Fine volumetric analysis of the cerebral ventricular system in schizophrenia: further evidence for multifocal mild to moderate enlargementM Sanfilipo, T Lafargue, L Arena, et al.
The American Journal of Psychiatry|July 1, 1989
Dopamine blockade and clinical response: evidence for two biological subgroups of schizophreniaA Wolkin, F Barouche, A P Wolf, et al.
Psychopharmacology|January 1, 1996
Amphetamine and negative symptoms of schizophreniaM Sanfilipo, A Wolkin, B Angrist, et al.
The American Journal of Psychiatry|March 1, 1996
Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptomsA Wolkin, M Sanfilipo, E Duncan, et al.
American Journal of Physiologic Imaging|January 1, 1988
Regional glucose metabolism in chronic schizophreniaJ D Brodie, A Wolkin, A P Wolf, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Clinical Neuropharmacology|October 1, 1996
The study of neurotransmitter interactions using positron emission tomography and functional couplingR Schloesser, P Simkowitz, E J Bartlett, et al.
Biological Psychiatry|November 1, 1993
Elevated PLA2 activity in schizophrenics and other psychiatric patientsM Noponen, M Sanfilipo, K Samanich, et al.
The American Journal of Psychiatry|August 12, 1998
Structural magnetic resonance image averaging in schizophreniaA Wolkin, H Rusinek, G Vaid, et al.
The American Journal of Psychiatry|May 1, 1985
Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomographyA Wolkin, J Jaeger, J D Brodie, et al.
Archives of General Psychiatry|May 1, 1989
Dopamine receptor occupancy and plasma haloperidol levelsA Wolkin, J D Brodie, F Barouche, et al.
Schizophrenia Bulletin|February 7, 2001
Fine volumetric analysis of the cerebral ventricular system in schizophrenia: further evidence for multifocal mild to moderate enlargementM Sanfilipo, T Lafargue, L Arena, et al.
The American Journal of Psychiatry|July 1, 1989
Dopamine blockade and clinical response: evidence for two biological subgroups of schizophreniaA Wolkin, F Barouche, A P Wolf, et al.
Psychopharmacology|January 1, 1996
Amphetamine and negative symptoms of schizophreniaM Sanfilipo, A Wolkin, B Angrist, et al.
The American Journal of Psychiatry|March 1, 1996
Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptomsA Wolkin, M Sanfilipo, E Duncan, et al.
American Journal of Physiologic Imaging|January 1, 1988
Regional glucose metabolism in chronic schizophreniaJ D Brodie, A Wolkin, A P Wolf, et al.
Pageof 4